Next-generation, selective kinase medicines

Our proprietary scientific platform enables us to rapidly and reproducibly design medicines that selectively target kinase drivers of disease, enabling improved potency, less off-target activity and an increased probability of clinical success.

Discovered by Blueprint Medicines, pralsetinib is an investigational RET inhibitor for certain RET-altered solid tumors.

Cometriq® (cabozantinib), an FDA-approved multi-kinase inhibitor for advanced medullary thyroid cancer (MTC)

Caprelsa® (vandetanib), an FDA-approved multi-kinase inhibitor for advanced MTC

Kinome illustrations reproduced courtesy of Cell Signaling Technology, Inc. (CSTI).

A focused strategy

Our research focuses on kinase targets where we believe our technology can lead to meaningful improvements in treatment.


Well-recognized kinases that are difficult to target with existing technologies


Mutant kinases that have become resistant to current treatments

Novel biology

New targets identified with our computational and cell biology expertise